UA76940C2 - Polycation bioconjugates capable of transporting active substances of different types in patient's body - Google Patents

Polycation bioconjugates capable of transporting active substances of different types in patient's body Download PDF

Info

Publication number: UA76940C2
Authority: UA; Ukraine
Prior art keywords: molecules; general formula; polycationic; bioconjugates; bioconjugate
Prior art date: 1999-06-29

Application number

UA2002010706A

Other languages

English (en)

Ukrainian (uk)

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-06-29

Filing date

2000-06-28

Publication date

2006-10-16

2000-06-28 Application filed filed Critical

2006-10-16 Publication of UA76940C2 publication Critical patent/UA76940C2/uk

Links

239000013543 active substance Substances 0.000 title abstract description 5
239000000126 substance Substances 0.000 claims abstract description 22
230000021615 conjugation Effects 0.000 claims abstract description 10
125000000524 functional group Chemical group 0.000 claims abstract description 5
230000003014 reinforcing effect Effects 0.000 claims description 54
150000001875 compounds Chemical class 0.000 claims description 37
125000000129 anionic group Chemical group 0.000 claims description 30
230000002708 enhancing effect Effects 0.000 claims description 30
125000002091 cationic group Chemical group 0.000 claims description 20
230000001028 anti-proliverative effect Effects 0.000 claims description 18
206010028980 Neoplasm Diseases 0.000 claims description 14
230000000694 effects Effects 0.000 claims description 12
125000003277 amino group Chemical group 0.000 claims description 11
108090000765 processed proteins & peptides Chemical group 0.000 claims description 9
230000001404 mediated effect Effects 0.000 claims description 8
239000000178 monomer Substances 0.000 claims description 8
108020004707 nucleic acids Proteins 0.000 claims description 6
102000039446 nucleic acids Human genes 0.000 claims description 6
102000004196 processed proteins & peptides Human genes 0.000 claims description 6
239000012634 fragment Substances 0.000 claims description 5
229920001184 polypeptide Polymers 0.000 claims description 5
241000894006 Bacteria Species 0.000 claims description 4
239000000969 carrier Substances 0.000 claims description 4
229940088597 hormone Drugs 0.000 claims description 4
239000005556 hormone Substances 0.000 claims description 4
150000007523 nucleic acids Chemical class 0.000 claims description 4
230000005298 paramagnetic effect Effects 0.000 claims description 4
238000005728 strengthening Methods 0.000 claims description 4
239000000074 antisense oligonucleotide Substances 0.000 claims description 3
238000012230 antisense oligonucleotides Methods 0.000 claims description 3
150000001720 carbohydrates Chemical group 0.000 claims description 3
235000014633 carbohydrates Nutrition 0.000 claims description 3
239000003667 hormone antagonist Substances 0.000 claims description 3
229940051026 immunotoxin Drugs 0.000 claims description 3
230000002637 immunotoxin Effects 0.000 claims description 3
239000002596 immunotoxin Substances 0.000 claims description 3
231100000608 immunotoxin Toxicity 0.000 claims description 3
241000894007 species Species 0.000 claims description 3
239000011782 vitamin Substances 0.000 claims description 3
235000013343 vitamin Nutrition 0.000 claims description 3
229940088594 vitamin Drugs 0.000 claims description 3
229930003231 vitamin Natural products 0.000 claims description 3
239000004970 Chain extender Substances 0.000 claims description 2
102000004127 Cytokines Human genes 0.000 claims description 2
108090000695 Cytokines Proteins 0.000 claims description 2
108090000288 Glycoproteins Proteins 0.000 claims description 2
102000003886 Glycoproteins Human genes 0.000 claims description 2
102000015636 Oligopeptides Human genes 0.000 claims description 2
108010038807 Oligopeptides Proteins 0.000 claims description 2
150000001413 amino acids Chemical group 0.000 claims description 2
230000000844 anti-bacterial effect Effects 0.000 claims description 2
239000000427 antigen Substances 0.000 claims description 2
102000036639 antigens Human genes 0.000 claims description 2
108091007433 antigens Proteins 0.000 claims description 2
239000002872 contrast media Substances 0.000 claims description 2
239000000824 cytostatic agent Substances 0.000 claims description 2
230000001085 cytostatic effect Effects 0.000 claims description 2
239000002502 liposome Substances 0.000 claims description 2
150000003628 tricarboxylic acids Chemical group 0.000 claims description 2
201000011510 cancer Diseases 0.000 claims 3
125000002252 acyl group Chemical group 0.000 claims 2
230000000890 antigenic effect Effects 0.000 claims 2
GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 1
108091034117 Oligonucleotide Proteins 0.000 claims 1
241001482237 Pica Species 0.000 claims 1
229940118377 Vitamin antagonist Drugs 0.000 claims 1
239000005557 antagonist Substances 0.000 claims 1
230000002924 anti-infective effect Effects 0.000 claims 1
150000001991 dicarboxylic acids Chemical group 0.000 claims 1
230000004069 differentiation Effects 0.000 claims 1
210000004124 hock Anatomy 0.000 claims 1
208000015181 infectious disease Diseases 0.000 claims 1
150000002632 lipids Chemical class 0.000 claims 1
239000008194 pharmaceutical composition Substances 0.000 claims 1
210000002105 tongue Anatomy 0.000 claims 1
238000012876 topography Methods 0.000 claims 1
239000003623 enhancer Substances 0.000 abstract description 14
108090000623 proteins and genes Proteins 0.000 abstract description 8
230000000845 anti-microbial effect Effects 0.000 abstract description 7
230000004663 cell proliferation Effects 0.000 abstract description 4
230000006870 function Effects 0.000 abstract description 3
241000124008 Mammalia Species 0.000 abstract description 2
238000004519 manufacturing process Methods 0.000 abstract description 2
230000003211 malignant effect Effects 0.000 abstract 1
CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Substances Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 37
229910000042 hydrogen bromide Inorganic materials 0.000 description 34
210000004027 cell Anatomy 0.000 description 29
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 24
238000000034 method Methods 0.000 description 19
230000001965 increasing effect Effects 0.000 description 13
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 12
230000000840 anti-viral effect Effects 0.000 description 11
238000002474 experimental method Methods 0.000 description 11
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
210000004881 tumor cell Anatomy 0.000 description 8
238000003756 stirring Methods 0.000 description 7
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 6
239000000047 product Substances 0.000 description 6
102000005962 receptors Human genes 0.000 description 6
108020003175 receptors Proteins 0.000 description 6
238000006467 substitution reaction Methods 0.000 description 6
239000002253 acid Substances 0.000 description 5
239000012467 final product Substances 0.000 description 5
230000002401 inhibitory effect Effects 0.000 description 5
230000005764 inhibitory process Effects 0.000 description 5
239000002244 precipitate Substances 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
150000007513 acids Chemical class 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
229960004316 cisplatin Drugs 0.000 description 4
230000000670 limiting effect Effects 0.000 description 4
238000002595 magnetic resonance imaging Methods 0.000 description 4
239000000203 mixture Substances 0.000 description 4
229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
235000017557 sodium bicarbonate Nutrition 0.000 description 4
238000012546 transfer Methods 0.000 description 4
230000004614 tumor growth Effects 0.000 description 4
NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
241000283984 Rodentia Species 0.000 description 3
241000700605 Viruses Species 0.000 description 3
150000001768 cations Chemical class 0.000 description 3
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
231100000915 pathological change Toxicity 0.000 description 3
230000036285 pathological change Effects 0.000 description 3
230000035755 proliferation Effects 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
108020000948 Antisense Oligonucleotides Proteins 0.000 description 2
241000219112 Cucumis Species 0.000 description 2
235000015510 Cucumis melo subsp melo Nutrition 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
235000001014 amino acid Nutrition 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
230000008859 change Effects 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
235000012000 cholesterol Nutrition 0.000 description 2
238000000502 dialysis Methods 0.000 description 2
238000001035 drying Methods 0.000 description 2
RJOJUSXNYCILHH-UHFFFAOYSA-N gadolinium(3+) Chemical compound [Gd+3] RJOJUSXNYCILHH-UHFFFAOYSA-N 0.000 description 2
239000011521 glass Substances 0.000 description 2
230000006872 improvement Effects 0.000 description 2
229910021645 metal ion Inorganic materials 0.000 description 2
230000001717 pathogenic effect Effects 0.000 description 2
239000000813 peptide hormone Substances 0.000 description 2
235000018102 proteins Nutrition 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
238000012552 review Methods 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
239000007787 solid Substances 0.000 description 2
230000035322 succinylation Effects 0.000 description 2
238000010613 succinylation reaction Methods 0.000 description 2
239000013589 supplement Substances 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
238000004809 thin layer chromatography Methods 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
210000003934 vacuole Anatomy 0.000 description 2
MEXAGTSTSPYCEP-JEDNCBNOSA-N (2s)-2,6-diaminohexanoic acid;hydrobromide Chemical compound Br.NCCCC[C@H](N)C(O)=O MEXAGTSTSPYCEP-JEDNCBNOSA-N 0.000 description 1
AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 1
FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
LRYZPFWEZHSTHD-HEFFAWAOSA-O 2-[[(e,2s,3r)-2-formamido-3-hydroxyoctadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium Chemical class CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](NC=O)COP(O)(=O)OCC[N+](C)(C)C LRYZPFWEZHSTHD-HEFFAWAOSA-O 0.000 description 1
108010079709 Angiostatins Proteins 0.000 description 1
102000012936 Angiostatins Human genes 0.000 description 1
108010002913 Asialoglycoproteins Proteins 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
SSTPBQDODAUKQM-UHFFFAOYSA-M C(CCC(=O)O)(=O)[O-].S(=O)(=O)(O)O.[Na+] Chemical compound C(CCC(=O)O)(=O)[O-].S(=O)(=O)(O)O.[Na+] SSTPBQDODAUKQM-UHFFFAOYSA-M 0.000 description 1
102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
101100291267 Drosophila melanogaster Miga gene Proteins 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
108010079505 Endostatins Proteins 0.000 description 1
OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
241000233866 Fungi Species 0.000 description 1
229910052688 Gadolinium Inorganic materials 0.000 description 1
241001547860 Gaya Species 0.000 description 1
102000009465 Growth Factor Receptors Human genes 0.000 description 1
108010009202 Growth Factor Receptors Proteins 0.000 description 1
208000026350 Inborn Genetic disease Diseases 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
241001529936 Murinae Species 0.000 description 1
241000283965 Ochotona princeps Species 0.000 description 1
240000000220 Panda oleosa Species 0.000 description 1
235000016496 Panda oleosa Nutrition 0.000 description 1
208000037273 Pathologic Processes Diseases 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
102000015731 Peptide Hormones Human genes 0.000 description 1
108010038988 Peptide Hormones Proteins 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
241000270295 Serpentes Species 0.000 description 1
241000350393 Sinna Species 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
102000007238 Transferrin Receptors Human genes 0.000 description 1
108010033576 Transferrin Receptors Proteins 0.000 description 1
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
206010052428 Wound Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 1
CZCSLHYZEQSUNV-UHFFFAOYSA-N [Na].OB(O)O Chemical compound [Na].OB(O)O CZCSLHYZEQSUNV-UHFFFAOYSA-N 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000000843 anti-fungal effect Effects 0.000 description 1
230000000842 anti-protozoal effect Effects 0.000 description 1
230000000692 anti-sense effect Effects 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
239000003904 antiprotozoal agent Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
238000001479 atomic absorption spectroscopy Methods 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical group OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
230000032823 cell division Effects 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
230000001055 chewing effect Effects 0.000 description 1
150000001841 cholesterols Chemical class 0.000 description 1
WLNARFZDISHUGS-MIXBDBMTSA-N cholesteryl hemisuccinate Chemical compound C1C=C2C[C@@H](OC(=O)CCC(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 WLNARFZDISHUGS-MIXBDBMTSA-N 0.000 description 1
238000010367 cloning Methods 0.000 description 1
230000003021 clonogenic effect Effects 0.000 description 1
230000005757 colony formation Effects 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
230000001268 conjugating effect Effects 0.000 description 1
239000002178 crystalline material Substances 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
239000003814 drug Substances 0.000 description 1
230000005684 electric field Effects 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
102000006815 folate receptor Human genes 0.000 description 1
108020005243 folate receptor Proteins 0.000 description 1
UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
210000005095 gastrointestinal system Anatomy 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
208000016361 genetic disease Diseases 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
150000002327 glycerophospholipids Chemical class 0.000 description 1
210000004013 groin Anatomy 0.000 description 1
230000012010 growth Effects 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
239000003630 growth substance Substances 0.000 description 1
230000036541 health Effects 0.000 description 1
230000002519 immonomodulatory effect Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
235000015110 jellies Nutrition 0.000 description 1
239000008274 jelly Substances 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
210000005229 liver cell Anatomy 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
208000003747 lymphoid leukemia Diseases 0.000 description 1
235000018977 lysine Nutrition 0.000 description 1
150000002669 lysines Chemical class 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
229920001542 oligosaccharide Polymers 0.000 description 1
150000002482 oligosaccharides Chemical class 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
230000001151 other effect Effects 0.000 description 1
239000005022 packaging material Substances 0.000 description 1
125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
230000026792 palmitoylation Effects 0.000 description 1
206010033675 panniculitis Diseases 0.000 description 1
230000009054 pathological process Effects 0.000 description 1
229960003330 pentetic acid Drugs 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
230000010287 polarization Effects 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
239000003223 protective agent Substances 0.000 description 1
229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
230000010076 replication Effects 0.000 description 1
235000003441 saturated fatty acids Nutrition 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
239000013049 sediment Substances 0.000 description 1
238000009097 single-agent therapy Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
210000004304 subcutaneous tissue Anatomy 0.000 description 1
229940014800 succinic anhydride Drugs 0.000 description 1
238000004114 suspension culture Methods 0.000 description 1
230000009897 systematic effect Effects 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
238000012360 testing method Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000037317 transdermal delivery Effects 0.000 description 1
102000003390 tumor necrosis factor Human genes 0.000 description 1
230000001875 tumorinhibitory effect Effects 0.000 description 1
235000021122 unsaturated fatty acids Nutrition 0.000 description 1
150000004670 unsaturated fatty acids Chemical class 0.000 description 1
238000005406 washing Methods 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Polyamides (AREA)
Materials For Medical Uses (AREA)
Polyesters Or Polycarbonates (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

UA2002010706A 1999-06-29 2000-06-28 Polycation bioconjugates capable of transporting active substances of different types in patient's body UA76940C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
HU9902217A HUP9902217A3 (en)	1999-06-29	1999-06-29	Polycation based bioconjugates and process for producing thereof
PCT/HU2000/000061 WO2001000242A2 (en)	1999-06-29	2000-06-28	Polycation-based bioconjugates

Publications (1)

Publication Number	Publication Date
UA76940C2 true UA76940C2 (en)	2006-10-16

Family

ID=89998595

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA2002010706A UA76940C2 (en)	1999-06-29	2000-06-28	Polycation bioconjugates capable of transporting active substances of different types in patient's body

Country Status (23)

Country	Link
US (2)	US6727347B1 (de)
EP (1)	EP1202748B1 (de)
JP (1)	JP2003503363A (de)
KR (1)	KR100795093B1 (de)
CN (1)	CN1371288A (de)
AT (1)	ATE408420T1 (de)
AU (1)	AU784031B2 (de)
BR (1)	BR0012633A (de)
CA (1)	CA2377074A1 (de)
CZ (1)	CZ20014701A3 (de)
DE (1)	DE60040294D1 (de)
EE (1)	EE200100715A (de)
HU (1)	HUP9902217A3 (de)
IL (2)	IL147380A0 (de)
MX (1)	MXPA02000450A (de)
NO (1)	NO20016391L (de)
NZ (1)	NZ516666A (de)
PL (1)	PL353933A1 (de)
RU (1)	RU2250782C2 (de)
SK (1)	SK19222001A3 (de)
UA (1)	UA76940C2 (de)
WO (1)	WO2001000242A2 (de)
ZA (1)	ZA200200266B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HUP9902217A3 (en) *	1999-06-29	2002-07-29	Szegoe Peter	Polycation based bioconjugates and process for producing thereof
AU8149901A (en) *	2000-03-21	2001-10-03	Wisconsin Alummi Res Foundatio	Methods and reagents for regulation of cellular responses in biological systems
EP1615665A4 (de) *	2003-04-10	2010-10-06	3M Innovative Properties Co	Abgabe von die immunantwort modifizierenden verbindungen
RU2270690C1 (ru) *	2004-06-11	2006-02-27	Государственный научный центр вирусологии и биотехнологии "Вектор" (ГНЦ ВБ "Вектор")	Комплексное анти-вич соединение
US8168922B2 (en) *	2004-10-18	2012-05-01	Lincoln Global, Inc.	Self-shielded flux cored electrode
US7834065B2 (en) *	2005-01-31	2010-11-16	Bmg Incorporated	Medical-use two part reactive adhesive and medical-use resin having self-degradation property
JP4989039B2 (ja) *	2005-04-27	2012-08-01	Ｊｎｃ株式会社	核酸複合体及びそれを用いる細胞内への核酸導入方法
TW200800235A (en) *	2005-10-18	2008-01-01	Otsuka Pharma Co Ltd	Carrier composition for nucleic acid transport
CN102124098B (zh)	2008-06-27	2014-03-12	博傲沃德株式会社	细胞及组织的冷冻保存用组合物
CN101891889B (zh) *	2010-08-18	2012-05-23	中国科学院长春应用化学研究所	阳离子聚合物及其制备方法
US8541556B1 (en)	2012-03-02	2013-09-24	Empire Technology Development Llc	Lignin derivatives and uses thereof
US9095142B2 (en)	2012-06-28	2015-08-04	Empire Technology Development Llc	Lignin derivatives having polycations and uses thereof
EP2944195A1 (de) *	2014-05-15	2015-11-18	Monier Tadros	Negativ geladene Matrix und Verwendung davon

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4701521A (en)	1978-07-17	1987-10-20	The Trustees Of Boston University	Method of effecting cellular uptake of molecules
US4847240A (en)	1978-01-16	1989-07-11	The Trustees Of Boston University	Method of effecting cellular uptake of molecules
JPS6356501A (ja) *	1986-08-26	1988-03-11	Chisso Corp	アフイニテイークロマトグラフイー用カラム充填剤及びその製造方法
HU202553B (en)	1987-10-21	1991-03-28	Mta Kutatas Es Szervezetelemzo	Process for producing isopolypeptides composed of diamino monokarboxylic acids and pharmaceutical compositions comprising same, as well as plant protective comprising polyisolysine
JPH0413741A (ja) *	1990-05-02	1992-01-17	Chisso Corp	ペクチン・ポリリシン高分子電解質複合体
JPH05246963A (ja) *	1992-03-02	1993-09-24	Kanegafuchi Chem Ind Co Ltd	ε−ポリリジン誘導体
DE4331011A1 (de) *	1993-09-13	1995-03-16	Bayer Ag	Nukleinsäuren-bindende Oligomere mit C-Verzweigung für Therapie und Diagnostik
EP0915832B1 (de) *	1996-08-05	2002-10-02	Prolinx, Inc.	Komplexbildner für boronverbindung und hochstabile komplexe
JP4606524B2 (ja) *	1997-11-19	2011-01-05	チッソ株式会社	ポリリジン、及びポリリジンの製造方法、及びポリリジン組成物、及びエンドトキシンを除去する医薬品の生産方法
HUP9902217A3 (en) *	1999-06-29	2002-07-29	Szegoe Peter	Polycation based bioconjugates and process for producing thereof

1999
- 1999-06-29 HU HU9902217A patent/HUP9902217A3/hu active IP Right Revival
2000
- 2000-06-28 DE DE60040294T patent/DE60040294D1/de not_active Expired - Fee Related
- 2000-06-28 CN CN00812216A patent/CN1371288A/zh active Pending
- 2000-06-28 BR BR0012633-0A patent/BR0012633A/pt not_active IP Right Cessation
- 2000-06-28 WO PCT/HU2000/000061 patent/WO2001000242A2/en not_active Ceased
- 2000-06-28 AT AT00944116T patent/ATE408420T1/de not_active IP Right Cessation
- 2000-06-28 PL PL00353933A patent/PL353933A1/xx unknown
- 2000-06-28 CA CA002377074A patent/CA2377074A1/en not_active Abandoned
- 2000-06-28 NZ NZ516666A patent/NZ516666A/en unknown
- 2000-06-28 SK SK1922-2001A patent/SK19222001A3/sk unknown
- 2000-06-28 RU RU2002102071/15A patent/RU2250782C2/ru not_active IP Right Cessation
- 2000-06-28 US US10/018,806 patent/US6727347B1/en not_active Expired - Fee Related
- 2000-06-28 IL IL14738000A patent/IL147380A0/xx active IP Right Grant
- 2000-06-28 KR KR1020017016890A patent/KR100795093B1/ko not_active Expired - Fee Related
- 2000-06-28 UA UA2002010706A patent/UA76940C2/uk unknown
- 2000-06-28 MX MXPA02000450A patent/MXPA02000450A/es active IP Right Grant
- 2000-06-28 AU AU58351/00A patent/AU784031B2/en not_active Ceased
- 2000-06-28 EE EEP200100715A patent/EE200100715A/xx unknown
- 2000-06-28 CZ CZ20014701A patent/CZ20014701A3/cs unknown
- 2000-06-28 JP JP2001505949A patent/JP2003503363A/ja active Pending
- 2000-06-28 EP EP00944116A patent/EP1202748B1/de not_active Expired - Lifetime
2001
- 2001-12-27 IL IL147380A patent/IL147380A/en not_active IP Right Cessation
- 2001-12-27 NO NO20016391A patent/NO20016391L/no not_active Application Discontinuation
2002
- 2002-01-11 ZA ZA200200266A patent/ZA200200266B/xx unknown
2004
- 2004-02-23 US US10/782,962 patent/US7090846B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CZ20014701A3 (cs)	2002-06-12
EE200100715A (et)	2003-02-17
ATE408420T1 (de)	2008-10-15
US7090846B2 (en)	2006-08-15
RU2250782C2 (ru)	2005-04-27
IL147380A0 (en)	2002-08-14
HU9902217D0 (en)	1999-08-30
DE60040294D1 (de)	2008-10-30
US6727347B1 (en)	2004-04-27
NO20016391D0 (no)	2001-12-27
CN1371288A (zh)	2002-09-25
US20040220083A1 (en)	2004-11-04
AU5835100A (en)	2001-01-31
SK19222001A3 (sk)	2004-05-04
HUP9902217A3 (en)	2002-07-29
CA2377074A1 (en)	2001-01-04
MXPA02000450A (es)	2002-07-02
KR100795093B1 (ko)	2008-01-17
WO2001000242A2 (en)	2001-01-04
ZA200200266B (en)	2003-06-25
EP1202748A2 (de)	2002-05-08
JP2003503363A (ja)	2003-01-28
PL353933A1 (en)	2003-12-15
AU784031B2 (en)	2006-01-19
EP1202748B1 (de)	2008-09-17
WO2001000242A3 (en)	2001-11-22
NZ516666A (en)	2004-04-30
KR20020031352A (ko)	2002-05-01
NO20016391L (no)	2002-02-04
IL147380A (en)	2007-02-11
HUP9902217A2 (hu)	2001-04-28
BR0012633A (pt)	2002-04-02

Publication	Publication Date	Title
Sun et al.	2017	RETRACTED ARTICLE: siRNA-loaded poly (histidine-arginine) 6-modified chitosan nanoparticle with enhanced cell-penetrating and endosomal escape capacities for suppressing breast tumor metastasis
DE69528363T2 (de)	2003-05-15	Neue nukleinsaure-polymer komplexe, verfahren zur deren herstellung und verwendung zur transfektion von zellen
Ye et al.	2013	A novel lactoferrin-modified β-cyclodextrin nanocarrier for brain-targeting drug delivery
US20060127310A1 (en)	2006-06-15	Amplification of biotin-mediated targeting
UA76940C2 (en)	2006-10-16	Polycation bioconjugates capable of transporting active substances of different types in patient's body
JP2007521247A (ja)	2007-08-02	生体適合性−遺伝子送達剤としての新規カチオン性リポポリマー
JP2002543111A (ja)	2002-12-17	ポリマーを使用する葉酸で仲介された腫瘍細胞へのターゲッティングの増幅
JP2003506319A (ja)	2003-02-18	ビタミンに関連したデュアルターゲッティング治療法
US9849190B2 (en)	2017-12-26	Peptide having cancer selective translocation function and use thereof
CN110114367B (zh)	2023-03-31	Vap多肽及其在制备靶向诊疗肿瘤药物中的应用
WO2024067500A1 (zh)	2024-04-04	反义核酸糖基缀合物及其制备方法和在肝癌治疗中的应用
CN115151278B (zh)	2025-08-22	用于核酸疗法的靶向肿瘤的多肽纳米颗粒递送系统
CN118105501A (zh)	2024-05-31	一种在体构建CAR-M细胞疗法的靶向性mRNA-LNP递送系统及制法和应用
WO2023165595A1 (zh)	2023-09-07	一类可用于活性分子递送的可降解脂质体及其纳米复合物
US20120220647A1 (en)	2012-08-30	Nano-hybrid of targetable sirna-layered inorganic hydroxide, manufacturing method thereof, and pharmaceutical composition for treating tumor comprising the nano-hybrid
KR101809795B1 (ko)	2017-12-18	폴리올계 삼투압적 폴리디자일리톨 폴리머 유전자 전달체 및 이의 용도
CN103417984A (zh)	2013-12-04	靶向脑胶质瘤双载药纳米递释系统及其制备方法
KR20120097865A (ko)	2012-09-05	간세포 표적 유전자 전달체로서 갈락토실화 폴리에틸렌글리콜-키토산-그라프트-스페르민 공중합체 및 이를 이용한 유전자 치료
CN117414440A (zh)	2024-01-19	一种抗肿瘤的噬菌体-阿霉素复合物及其制备方法和应用
US20120035320A1 (en)	2012-02-09	Polyacridine nucleic acid delivery peptide complexes
KR20230155895A (ko)	2023-11-13	글루타치온-s-전이효소 및 항체 결합 도메인을 포함하는 융합 단백질 및 이의 용도
CN115279420A (zh)	2022-11-01	含有癌症干细胞特异性结合肽且与维生素b6结合的基于多元醇的聚二木糖醇基因转运体及癌症干细胞靶向治疗技术
Abbineni	2011	Engineered Bacteriophage Enabled Nanoprobes for SKBR-3 Cancer Cell Specific Imaging and Therapy